Skip to main content
Human Vaccines & Immunotherapeutics logoLink to Human Vaccines & Immunotherapeutics
. 2023 Nov 15;19(3):2275457. doi: 10.1080/21645515.2023.2275457

Building safety into CAR-T therapy

Daniel T Peters a, Barbara Savoldo b, Natalie S Grover c,✉
PMCID: PMC10760383  PMID: 37968136

ABSTRACT

Chimeric antigen receptor T cell (CAR-T) therapy is an innovative immunotherapeutic approach that utilizes genetically modified T-cells to eliminate cancer cells using the specificity of a monoclonal antibody (mAb) coupled to the potent cytotoxicity of the T-lymphocyte. CAR-T therapy has yielded significant improvements in relapsed/refractory B-cell malignancies. Given these successes, CAR-T has quickly spread to other hematologic malignancies and is being increasingly explored in solid tumors. From early clinical applications to present day, CAR-T cell therapy has been accompanied by significant toxicities, namely cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and on-target off-tumor (OTOT) effects. While medical management has improved for CRS and ICANS, the ongoing threat of refractory symptoms and unanticipated idiosyncratic toxicities highlights the need for more powerful safety measures. This is particularly poignant as CAR T-cell therapy continues to expand into the solid tumor space, where the risk of unpredictable toxicities remains high. We will review CAR-T as an immunotherapeutic approach including emergence of unique toxicities throughout development. We will discuss known and novel strategies to mitigate these toxicities; additional safety challenges in the treatment of solid tumors, and how the inducible Caspase 9 “safety switch” provides an ideal platform for continued exploration.

KEYWORDS: CAR-T, cellular therapy, inducible caspase 9, safety switch, CRS, ICANS

CAR-T overview

The chimeric antigen receptor (CAR) T-Cell treatment is an immunotherapy strategy that involves genetically engineering autologous or allogeneic T-cells to express a recombinant protein known as a CAR on the cell surface. The CAR is composed of three major components including an (1) ectodomain consisting of an extracellular antigen-binding domain linked via a (2) transmembrane region to an (3) intracellular signaling domain known as the endodomain. The net effect of the CAR-T cell is antigen-specific recognition and cytotoxic killing of any cell expressing the extracellular target antigen in a non-HLA restricted manner.

Transition to clinical use

Despite early interest in a number of solid tumor types including ovarian,1 kidney,2 and prostate3 cancers, it became clear that solid tumors had additional and substantial barriers to CAR-T cell therapy success including (1) effects of the tumor microenvironment (TME) on CAR-T cell-trafficking and persistence in vivo, (2) tumor polyclonality, (3) on-target, off-tumor (OTOT) adverse events. The focus would quickly shift to targeting the CD19 antigen in B-cell malignancies.

To each of these points: hematologic malignancies are simply more accessible to T-cells from a pathophysiologic standpoint than solid tumor cells. Furthermore, CD19 is a B lineage-associated antigen that is stable and expressed at a high copy number by most B-cell malignancies including leukemia and lymphoma. Lastly, OTOT is primarily prolonged B-cell aplasia and secondary hypogammaglobulinemia, which are easily mitigated. In 2011, clinical trials of second-generation CAR-T cells targeting CD19 in chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-ALL) produced unprecedented results including complete remission in heavily pretreated patients demonstrating a key proof of concept.4

In the present day, CAR-T cell therapies now have robust and maturing clinical data for their ability to mediate potent antitumor responses in relapsed and/or refractory (r/r) B-Cell leukemias and lymphomas and multiple myeloma leading to FDA approval of multiple CAR-T cell products.

Review of common CAR-T toxicities

Along with impressive response rates, it was quickly discovered that CAR-T therapy carries the risk of potentially severe systemic toxicities defined by profound and generalized immune system activation. A constellation of fever, hypotension, and respiratory distress would come to define the cytokine release syndrome (CRS) and be noted across all early CAR-T trials with rates as high as 56–100% of patients treated with CD19 CAR-T cells for relapsed/refractory B-ALL.5 A lesser population of patients would develop nonspecific, variable neurologic toxicities which is now known as immune effector cell neurotoxicity syndrome (ICANS). Diagnosis, grading, and treatment paradigms for both CRS and ICANS have evolved significantly over the years and is now much more standardized and algorithmic based on the grading schema for each with the ASTCT consensus grading scale adapted by most institutions.6

We will focus mainly on these acute, inflammatory toxicities of CAR-T therapy in the context of adult patients treated with CD19-targeted commercial products, though we will also look to failed CAR-T trials of the past to illustrate the breadth of potential OTOT toxicities as the clinical application of CAR-T and other adoptive T-cell therapies (i.e. TCR, TILs) expands in the future. Long-term sequalae of commercial CAR-T products are less well described but include increased infectious risk, hypogammaglobulinemia, and persistent cytopenias7 which will not be reviewed here.

Cytokine Release Syndrome (CRS)

Following CAR-T cell binding to their target antigen, downstream cell signaling initiates T-cell expansion and massive production of cytotoxic molecules and cytokines including but not limited to TNFα, IFNγ, IL-1β, IL-2, IL-5, IL-6, IL-8, and IL-10, GM-CSF. Furthermore, the rapid death of the target cell elaborates additional cytokines and inflammatory mediators, adding to the cascade. It is important to note that many of these inflammatory mediators, particularly IL-6 (felt to be a major driver of the syndrome), are not produced by either CAR or unmodified T cells, but rather by incited myeloid cells (monocytes, macrophages, etc.) downstream from the activating event.8 CRS is the systemic response to the sudden and excessive release of these inflammatory mediators, all of which have a litany of nonspecific and organ-specific effects in part driven by endothelial injury/dysfunction. Post-infusion onset of symptoms is variable, typically peaking at 2–7 days, though delays up to 3 weeks are reported.9

Clinically, fever is the hallmark of CRS, though rigors, tachycardia, hypotension, tachypnea, and hypoxemia are also commonly observed. However, all organ systems may be affected by CRS and patients develop rashes, acute renal injury, hepatobiliary injury, arrhythmia, cardiomyopathy,10 and coagulopathy.11 CRS is mild and reversible in most cases but can progress to refractory distributive shock with multiorgan failure. Additionally, an emergent condition known as immune effector cell-associated HLH-like syndrome (IEC-HS) can develop continuously with or independently of CRS, though the exact pathophysiology is a subject of further study.12

Aside from physiologic toxicity, CRS is associated with significant financial toxicity. A recent study assessing the cost associated with CAR-T cell therapy estimated that CRS may cost a patient $36 000 to $50 000 in severe cases, adding to an already expensive treatment with an average cost of $373 000–$475 000 depending on the product.13

Neurologic toxicities

ICANS

Neurologic toxicities were previously considered in aggregate with CRS. With increasing CAR-T therapy experience, immune effector cell-associated neurotoxicity syndrome (ICANS), has been developed as a distinct clinical entity that defines neurologic symptoms that can occur after CAR-T infusion. This may co-occur with CRS or more commonly following the resolution of CRS. Usually this occurs within 3–4 weeks of cell infusion, though cases of delayed onset >4 weeks are described. ICANS manifests as difficulty concentrating, confusion, delirium, lethargy, aphasia, tremor, and seizures. In rare cases, malignant cerebral edema can develop and may lead to death. The mechanisms causing ICANS are not completely understood, but important factors probably include release of neurotoxic substances by CAR-T cells, bystander immune cells, and lysed tumor cells; alteration of the blood brain barrier with endothelial activation as a contributor; and potentially the presence of CAR-T cells in the CNS related to CD19 expression on brain mural cells.14–17

MNTs

A neurologic toxicity distinct from ICANS, termed movement and neurocognitive treatment-emergent adverse events (MNTs) were recently described in patients treated with BCMA CAR-T cell therapy for multiple myeloma. MNT resembles a parkinsonian syndrome though with neither evidence of substantia nigra degeneration on neuropathology nor expression of BCMA in brain parenchyma to invoke an on target, off tumor toxicity. There is no established treatment for this entity as of this writing.18

Clinical management and prevention of CRS/ICANS

Initial concerns about decreasing CAR-T expansion and efficacy with corticosteroids and/or tocilizumab (IL-6 R monoclonal antibody) use led to a general sentiment of withholding either treatment for CRS/ICANS as long as possible (i.e. until higher CRS grade reached). However, treatment with tocilizumab does not affect CAR-T expansion based on experiences with tisagenlecleucel.19 Corticosteroids are also not currently shown to affect response rates, or durability of response in clinical trials, though the long-term effects are not determined.20 Taken together, clinical practice has globally shifted to earlier and more aggressive use of tocilizumab and corticosteroids to manage CRS before preventable organ toxicity occurs. Currently, tocilizumab and steroids comprise the standard of care, but there does remain a subset of patients who develop severe CRS that is refractory to these measures. Early identification of this high-risk subset as well as preemptive interventions in this population are an area of ongoing interest.

There are numerous pharmacologic interventions being investigated for severe and refractory CRS/ICANS employing three major strategies: (1) anti-cytokine-directed treatment, (2) T cell ablation, (3) tyrosine kinase inhibitors (TKIs). Anakinra (IL-1 R antagonist), siltuximab (IL-6 antagonist), empalumab (INF-γ-blocking antibody), and lenzilumab (anti GM-CSF antibody)8 target various CRS-associated cytokines with the benefit of not directly affecting the CAR-T cell product. T-cell ablation with antithymocyte globulin (ATG), alemtuzumab (anti-CD52), and cyclophosphamide are not well published in CRS/ICANS though are known to have potent T cytotoxic effects. This approach has the obvious disadvantage of destroying the CAR-T product and causing further native immunosuppression. TKIs including dasatinib (BCR-ABL inhibitor), ibrutinib (BTK inhibitor), and ruxolitinib (JAK inhibitor) have shown the ability to decrease secretion of culprit cytokines resulting in reduced CRS severity in preclinical data.21–24

Among other risk factors, development of CRS/ICANS has been associated with pre-treatment disease burden as well as CAR-T cell dose and peak expansion.5 As such, preventative approaches have been explored with these risk factors in mind. Several groups have evaluated the utility of tumor burden-based CAR-T cell dose reduction or split-dose strategies. While low-dose infusions trended toward higher relapse rates,25 a recent literature review suggests that a dose fractionation strategy may mitigate the incidence of CRS and ICANS, though additional studies are needed.26 Other investigators have assessed prophylactic dexamethasone, tocilizumab, and anakinra for all comers regardless of risk factors. In summary, prophylactic dexamethasone and anakinra were useful in decreasing CRS/ICANS with no decrease in efficacy on early follow-up.27,28 Prophylactic tocilizumab was observed to transiently increase IL-6 levels due to its mechanism of action in receptor blockade. This was felt to correlate with increased rates of ICANS versus the control (41% vs 28%) with a single case of cerebral edema in the prophylaxis group.29 Though the findings are somewhat controversial, most groups avoid prophylactic tocilizumab as a result.

On Target, Off Tumor (OTOT)

While phase 1 trials of first-generation CARs failed to show meaningful clinical tumor response in ovarian cancer,1 metastatic renal cell carcinoma,2,30 melanoma, and other tumor types, the field would gain first-hand experience with on-target, off-tumor toxicity (OTOT). There are several documented examples of this across organ systems including B-cell and plasma cell aplasia with CD19 and BCMA targeted CAR-T therapies;9 fatal pulmonary toxicity with CAR-T product targeting ERBB2 (HER2/Neu); hepatic toxicity with CAR-T targeting the antigen carboxyanhydrase-IX (CAIX);2,30 and fulminant myocarditis with a TCR targeting melanoma-associated antigen 3 (MAGEA3).31 Apart from B-cell aplasia related to CD19 targeting, the culprit antigens did not signal for toxic potential in pre-clinical testing.

In summary, the most common acute toxicities for CAR-T products in clinical use (CD19, BCMA) are CRS and ICANS. The management of CRS has improved markedly over the years since CAR-T therapies were first introduced and can now be managed relatively easily with early and aggressive use of tocilizumab and corticosteroids. ICANS has become slightly better defined, but the pathophysiology remains clouded. While early and aggressive use of steroids and antiepileptics have improved morbidity and mortality, this remains a substantial safety issue to be addressed. New neurologic toxicities (NMTs) are emerging in the BCMA-targeted CAR-T products that will need to be addressed and raises the specter of more unanticipated neurologic, organ-specific, or long-term toxicities even when the target antigen is not clearly present in the affected tissue. We expect the absolute magnitude of these problems to increase as CD19 and BCMA CAR-T products are approved for new specific indications (i.e. primary CNS lymphoma, CLL) and in earlier lines of therapy for B-cell malignancies and multiple myeloma, respectively.

We also anticipate the morbidity and mortality associated with OTOTs to increase as CAR-T therapies target a wider array of antigens on solid tumors or on hematologic tumors that are known to have heterogeneous or low levels of antigen expression, particularly AML. While no doubt there will be improvements in preclinical safety evaluation of TAAs, it is unlikely that CAR-T developers will be able to anticipate all OTOTs and especially unlikely to anticipate idiosyncratic cross-reactivity events, using the story of MAGEA3 as an example. As such, there remains a great need for rapid and complete eradication of CAR-T products as they are put to clinical use in humans to mitigate known, severe toxicities and protect our patients from unknown and late phase toxicities lying in wait.

Addressing CAR-T toxicity in platform development

There have been a number of innovative approaches to fine-tune the CAR-T cell for safety with several recent reviews provided for reference32–34 and a table (Table 1) summarizing some of the approaches. The approaches are impressively broad and include either modifying or re-imagining the CAR construct at each of the three basic components (the ectodomain, transmembrane region, and endodomain) or simply by adding on new ancillary features.

Table 1.

Genetic engineering approaches to improving CAR-T safety.

Approach Comment Reference
Ectodomain modification
scFv affinity Low affinity scFv mediates tumor killing without host tissue damage Ghorashian et al.35
humanized scFv Humanized scFV targeting CD19 in human pediatric ALL slightly decreased CRS/ICANS with similar efficacy Myers et al.36
IL-6 sink Non-functioning IL-6 receptor serves as a sink for locally elaborated IL-6 Tan et al.37
Hinge/TM modification
Hu19-CD828z Decreased rates of CRS/ICANS attributable to hinge/TM alteration rather than humanized scFv alone Brudno et al.38
Logic Gating    
AND-gate    
Split Recognition Expresses at least two CARs one with CD3z one with costimulatory domain (i.e. CD24, 4-1BB) and can only transduce signal when both are bound to antigen Lanitis et al.39
Reverse CAR Distinct peptide epitopes in place of scFv. An exogenous bi-specific engager is given which has two scFvs: one specific to distinct peptide epitope and the other recognizing a tumor-associated antigen Kittel-Boselli et al.40
Avid CAR Avidity-controlled CAR platform, designed to homodimerize upon dual antigen recognition conferring sufficient avidity for T cell activation Salzer et al.41
NOT-gate    
iCAR Contain inhibitory domains derived from PD-1 and CTLA-4. CAR- and iCAR-expressing T cells will kill cells expressing only the CAR antigen while sparing cells harboring both the CAR and iCAR antigens Fedorov et al.42
LOH-iCAR (NASCAR) Pairwise chimeric receptors that, together, are capable of allele sensing and detecting LOH events in cancer Hwang et al.43
AND-, AND/NOT- gate    
Co-LOCKR Utilizes a universal CAR specific to a recruitment peptide, which is placed in a ‘Latch’ sequence. The latch is linked to a soluble ‘Cage’ protein that is directed at the first tumor antigen. The recruitment peptide is sequestered by the Cage and is only exposed to engagement by the CAR when a competing ‘Key’ protein binds a second antigen present on the same tumor cell Lajoie et al.44
SynNotch Utilizes a constitutively expressed module which releases a synthetic TF only upon binding of antigen A. Upon translocation to the T cell nucleus, this TF drives the expression of a conventional CAR specific to antigen Choe et al.45
SUPRA CAR Universal, leucine zipper CAR-like receptor (zipCAR), which can bind a corresponding leucine zipper incorporated onto a soluble antigen-specific zipFv protein, enabling multiplexed control of T cell responses Cho et al.46
VIPER As below  
Pharmacologic Switch    
Dasatinib (OFF) Administration of dasatinib keeps CAR T cells in an inactive function “off” state Mestermann et al.21
Lenalidomide (ON) lenalidomide-inducible dimerization system with split CARs that required both lenalidomide and target antigen for activation Jan et al.47
Lenalidomide (OFF) lenalidomide-inducible CRL4CRBN-mediated ubiquitination and proteasomal degradation of a “super” degron-tagged CAR Jan et al.47
Tetracycline (ON) Gene of interest (CAR in this case) is under control of a tetracycline/doxycycline dependent transcriptional regulation Zhang et al.48
Protease-based (“SNIP CARs”)    
VIPER CAR (ON) Versatile Protease Regulatable CARs. A protease, NS3 is constitutively expressed in the CAR construct. Only when its inhibitor (grazoprevir) is given can the CAR be assembled and expressed Li et al.49
VIPER CAR (OFF) Split CAR with endodomain held together by NS3-binding peptide and an enzymatically inactive NS3 in series with the signaling domain. CAR is capable of cell signaling until protease inhibitor given which, competitively binds and breaks the linkage Li et al.49
CRASH-IT (OFF) Chemically Regulated SH2-delivered Inhibitory Tail. NS3-degron-PD1 inhibitory tail fusion protein is coexpressed with CAR. The fusion protein has constitutive inhibitory function of the CAR until asunaprevir/grazoprevir is administered. Sahillioglu et al.50
Suicide Genes    
mAB-mediated    
EGFRt Engineered cells constitutively express truncated EGFR which can be eliminated by administering anti-EGFR mAb, cetuximab. Paszkiewicz et al.51
RQ8R Engineered cells express polypeptide sequence derived from CD34 and CD20 (termed RQR8) which can be bound and eliminated by rituximab Philip et al.52
Gene-directed enzyme prodrug therapy (GDEPT)    
HSV TK Renders engineered cells sensitive to ganciclovir which disrupts cell cycling and leads to apoptosis Bonini et al.53
Dimerization induced    
Inducible Caspase 9 Administration and binding of AP1903 (rimiducid) to FKBP12-F36V leads to dimerization and activation of an inducible caspase 9-based suicide construct (iCaspase 9), which triggers apoptosis of the CAR-T cell. Di Stasi et al.54
Environmental Switching    
LINTAD Blue light induced CAR expression Huang et al.55
FUS Induced CARs induced via heat shock protein pathway using focal ultrasound (FUS) Wu et al.56
Hypoxia Inducible CARs Hypoxia-induced CAR expression via HIF pathway Kosti et al.57
Inflammation and hypoxia inducible CAR-T (CARTIV) TME-related hypoxia and inflammatory markers drive CAR expression Greenshpan et al.58

A notable example is the integration of logic-gated CAR constructs that utilize AND-, OR-, NOT-gate strategies; of which AND- gating results in improved target specificity to reduce OTOT. The gate is completed either through intrinsic CAR properties or reliance on an exogenous signal (dimerizing agent, small molecule, protease inhibitor, etc.). The synthetic Notch (synNotch) strategy is another combinatorial antigen recognition approach in which a synNotch receptor must be activated by a priming antigen before the authentic CAR is even expressed on the T-cell surface.45 Some groups have uncoupled the antigen binding unit from the CAR-T cell altogether creating “universal” CARs that engage the tumor using an exogenous mAb, peptide bridge, or BiTE that can easily be withheld if toxicities arise. Others have created alternative methods of CAR-T cell activity induction/switching using blue light, ultrasound, hypoxia, small molecules, and known pharmacologic (i.e. dasatinib, lenalidomide, doxycycline) agents as switches. Despite these innovative and effective approaches, there is not an “off switch” for CAR-T cells that have already engaged their target. In certain scenarios of life-threatening OTOT, there may be a need for rapid and complete abortion of T-cell activity that can may only be achieved through apoptosis.

Recognizing this need for a rapid and complete “off switch” several groups, including our own, have developed various suicide genes into the CAR construct. For example, Paszkiewicz et al.51 developed a truncated version of epidermal growth factor receptor (EGFRt) that is co-expressed on CD19 CAR-T cells and leads to effective elimination of CD19 CAR-T cells when an EGFR targeted antibody is administered in a murine model. This fits under the broad umbrella of suicide gene technologies which can be further subdivided by mechanism of action: (1) monoclonal antibody-mediated (as above), (2) gene-directed enzyme prodrug therapy (GDEPT) whereby an inert prodrug is metabolized to a toxin only in the gene-modified cells, and (3) dimerization induced.59 Our group has continued to utilize a dimerization induced safety switch for our CAR-T constructs, which we believe addresses a key need in mitigating safety concerns as adoptive cellular therapy applications rapidly expand.

The inducible Caspase9 (iCasp9) safety switch

Originally developed for the mitigation of graft vs. host disease (GVHD) in allogeneic stem cell transplant,54 the inducible Caspase 9 system is perfectly suited to manage the significant toxicities of CAR-T cells in their current applications – and likely even more valuable for solid tumor applications where OTOT toxicities may develop as new targets are explored.

Apoptotic genes including caspases eliminate cells by inducing cell death. Chimeric proteins composed of apoptotic pathway components linked to a dimerize-able drug-binding component have been developed.60,61 Administration of a non-therapeutic small molecule causes dimerization and activates the apoptotic pathway. In the inducible Caspase 9 (iC9)/AP1903 system, the chimeric protein is composed of an FKBP12-F36V domain linked to ΔCaspase 9, which is Caspase without its activator recruitment domain. The FKBP12 carries a substitution (F36V) that allows for the binding of synthetic dimeric ligands, in this case, rimiducid (RIM), which is an otherwise biologically inert and clinically safe compound.62

This platform is on display in an ongoing phase 1/2 trial (NCT03016377) for r/r B-ALL testing the safety and efficacy of autologous T lymphocytes genetically modified to express iC9, truncated low-affinity nerve growth factor receptor (ΔNGFR) (for selection and tracking purposes), and CD19 CAR (encoding 4-1BB). We reported the first case of administering a potentially ablative dose of RIM (0.4 mg/kg) showing that the intervention was able to rapidly eliminate CAR-T cells (>60% within 4 h, and > 90% within 24 h of RIM infusion) along with equally brisk resolution of severe, prolonged corticosteroid refractory ICANS.63

Given this patient’s rapid resolution of symptoms and reduction in iC9 CD19 CAR-T numbers, we sought to explore the effects of lower, potentially non-ablative doses of RIM in patients with CS-nonresponsive ICANS. We recently presented64 the clinical and pharmacodynamic correlates in 4 additional patients treated with rimiducid, two of which received full dose RIM 0.4 mg/kg and achieved complete resolution in ICANS by 5 days with rapid reduction in CAR-T cells by 4 h (83.6% and 98.6% reduction). The other two patients received the dose-reduced RIM 0.1 mg/kg with resolution of ICANS within 48 h. These patients also had a significant reduction in CAR-T cells by 4 h (88.6% and 88.1%). Rates of overall response at 4 weeks were 3/4 in RIM-treated subjects vs 9/9 in other reported subjects. No clear association between RIM pharmacokinetics and degree of CAR-T cell ablation has emerged, and it is possible that even lower doses might be necessary to discern this. Decreased response rate in RIM-treated patients raises concern for blunting of antileukemic activity of iC9 CD19 CAR-T cells. Both questions are subjects of active research.

Another notable trial utilizing the iC9 switch for a solid tumor application was recently published.65 Del Bufalo et al. reported their findings of a phase 1/2 trial utilizing the iC9 safety switch in a GD2 CAR (encoding 4-1BB) for pediatric neuroblastoma. A total of 27 heavily pretreated children were enrolled and received GD2-CART01. CRS occurred in 20/27 patients (74%) with only one Grade 3 CRS resolving rapidly with tocilizumab. A single patient developed an “altered level of consciousness” and received two doses of RIM (0.4 mg/kg). The workup would reveal brain hemorrhage as the etiology of the neurologic symptoms, but the effects of RIM on the CAR-T product were reported. As previously described in our work, there was a sharp decrease in circulating GD2-CART01 levels at 4 hours after infusion of RIM. Interestingly, a re-expanded population of the GD2-CART01 cells were detected at 6 weeks. This cell population was interrogated and determined to have retained full sensitivity to RIM in vitro suggesting that activation of the suicide gene preferentially eliminates activated gene-modified cells.

This raises the question of whether this re-expanded cell population would be capable of mediating on-target effector functions including both anti-tumor activity and OTOT. Reassuringly, any reemerging activity – favorable or not – would still be under the control of RIM, but further assessment is needed. Taken together, iC9 platform continues to build a portfolio of safe and reliable immune effector cell elimination in human trials spanning both hematologic and solid malignancies, without compromising disease activity.

Conclusion

As existing CAR-T cell trials mature and new trials emerge for both hematologic and solid tumor malignancies, so will new on-target, off-target, and idiosyncratic toxicities. Despite improved clinical management of CRS and ICANS, the perennial risk of unpredictable, untestable, and life-threatening toxicities is one of the biggest barriers to expansion of the field and a significant patient safety risk. It is our hope that the iC9 safety switch along with other promising genetic engineering approaches to CAR-T cell safety will ultimately allay these concerns and allow for the safe and rapid discovery of impactful treatments across all cancer types.

Funding Statement

The author(s) reported there is no funding associated with the work featured in this article.

Disclosure statement

N.G serves on the advisory board for Bristol Meyer Squib, Novartis, and Kite Pharmaceuticals

N. G. and B.S. have received previous research funding form Bellicum Pharmaceuticals.

D. P has no interests to declare.

References

  • 1.Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20):6106–8. doi: 10.1158/1078-0432.CCR-06-1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Lamers CHJ, Sleijfer S, Vulto AG, Kruit WHJ, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E.. Treatment of metastatic renal cell carcinoma with autologous T-Lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24(13):e20–e2. doi: 10.1200/JCO.2006.05.9964. [DOI] [PubMed] [Google Scholar]
  • 3.Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, Ramon J, Eshhar Z. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes1. Cancer Res. 2003;63:2470–6. [PubMed] [Google Scholar]
  • 4.Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med. 2011;365(8):725–33. doi: 10.1056/NEJMoa1103849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Sheth VS, Gauthier J. Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. Bone Marrow Transplant. 2021;56(3):552–66. doi: 10.1038/s41409-020-01134-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38. doi: 10.1016/j.bbmt.2018.12.758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Bücklein V, et al. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138(24):2499–513. doi: 10.1182/blood.2020010543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133(7):697–709. doi: 10.1182/blood-2018-10-881722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978–92. doi: 10.1200/JCO.21.01992. [DOI] [PubMed] [Google Scholar]
  • 10.Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502. doi: 10.1038/s41569-020-0348-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wang Y, Qi K, Cheng H, Cao J, Shi M, Qiao J, Yan Z, Jing G, Pan B, Sang W, et al. Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 patients with relapsed and refractory hematologic malignancies. Biol Blood Marrow Transplant. 2020;26(5):865–75. doi: 10.1016/j.bbmt.2019.11.027. [DOI] [PubMed] [Google Scholar]
  • 12.Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther. 2023;29(7):.e438.1–.e6. doi: 10.1016/j.jtct.2023.03.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Hernandez I, Prasad V, Gellad WF. Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 2018;4(7):994–6. doi: 10.1001/jamaoncol.2018.0977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Brudno JN, Lam N, Vanasse D, Shen Y-W, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, et al. Safety and feasibility of anti-CD19 CAR T cells with fully humanbinding domains in patients with B-cell lymphoma. Nat Med. 2020;26(2):270–80. doi: 10.1038/s41591-019-0737-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958–71. doi: 10.1158/2159-8290.CD-17-1319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, Yeung C, Liles WC, Wurfel M, Lopez JA, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–19. doi: 10.1158/2159-8290.CD-17-0698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell. 2020;183(1):126–42.e17. doi: 10.1016/j.cell.2020.08.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Cohen AD, Parekh S, Santomasso BD, Gállego Pérez-Larraya J, van de Donk NWCJ, Arnulf B, Mateos M-V, Lendvai N, Jackson CC, De Braganca KC, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2). doi: 10.1038/s41408-022-00629-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24(24):6175–84. doi: 10.1158/1078-0432.CCR-18-0758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Adkins R, Msn. Anp-C, Sherry: CAR T-cell therapy: adverse events and management. J Adv Pract Oncol. 2019;10(4):2019. doi: 10.6004/jadpro.2019.10.4.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H, Hudecek M, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med. 2019;11(499):eaau5907. doi: 10.1126/scitranslmed.aau5907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA, Lacey SF, June CH, Gill S. Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia. 2017;31(1):246–8. doi: 10.1038/leu.2016.262. [DOI] [PubMed] [Google Scholar]
  • 23.Pan J, Deng B, Ling Z, Song W, Xu J, Duan J, Wang Z, Chang AH, Feng X, Tan Y, et al. Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy. J Cell Mol Med. 2021;25(2):1089–99. doi: 10.1111/jcmm.16176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zi FM, Ye LL, Zheng JF, Cheng J, Wang QM. Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: a case report. Medicine. 2021;100(19):e25786. doi: 10.1097/MD.0000000000025786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Turtle CJ, Hanafi L-A, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123–38. doi: 10.1172/JCI85309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Frigault M, Rotte A, Ansari A, Gliner B, Heery C, Shah B. Dose fractionation of CAR-T cells. A systematic review of clinical outcomes. J Exp Clin Canc Res. 2023;42(1):2023. doi: 10.1186/s13046-022-02540-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Oluwole OO, Bouabdallah K, Muñoz J, De Guibert S, Vose JM, Bartlett NL, Lin Y, Deol A, McSweeney PA, Goy AH, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma. Br J Haematol. 2021;194(4):690–700. doi: 10.1111/bjh.17527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Strati P, Li X, Deng Q, Feng L, Sun R, Jallouk A, Adkins S, Cain T, Johncy S, Steiner RE, et al. Primary analysis of a pilot study of prophylactic anakinra to mitigate CAR T cell-associated toxicity in patients with relapsed or refractory large B-cell lymphoma. Blood. 2022;140(Supplement 1):7493–5. doi: 10.1182/blood-2022-157448. [DOI] [Google Scholar]
  • 29.Locke FL, Neelapu SS, Bartlett NL, Lekakis LJ, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, et al. Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin lymphoma (NHL). Blood. 2017;130(Suppl_1):1547–1547. doi: 10.1182/blood.V130.Suppl_1.1547.1547. [DOI] [Google Scholar]
  • 30.Lamers CH, Sleijfer S, Van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4):904–12. doi: 10.1038/mt.2013.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–71. doi: 10.1182/blood-2013-03-490565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Abken H. Building on synthetic immunology and T cell engineering: a brief journey through the history of chimeric antigen receptors. Hum Gene Ther. 2021;32(19–20):1011–28. doi: 10.1089/hum.2021.165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Wu Y, Huang Z, Harrison R, Liu L, Zhu L, Situ Y, Wang Y. Engineering CAR T cells for enhanced efficacy and safety. APL Bioeng. 2022;6(1). doi: 10.1063/5.0073746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Asmamaw Dejenie T, Markeshaw TG, Dessie Terefe G, Tadele Admasu, F., Wale Tesega, W., Chekol Abebe, E.. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Human Vaccin Immunother. 2022;18(6). doi: 10.1080/21645515.2022.2114254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, Albon SJ, Casanovas-Company J, Castro F, Popova B, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408–14. doi: 10.1038/s41591-019-0549-5. [DOI] [PubMed] [Google Scholar]
  • 36.Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, et al. Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol. 2021;39(27):3044–55. doi: 10.1200/jco.20.03458. Epub 20210622. PubMed PMID: 34156874; PubMed Central PMCID: PMCPMC9851702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tan AHJ, Vinanica N, Campana D. Chimeric antigen receptor–T cells with cytokine neutralizing capacity. Blood Adv. 2020;4(7):1419–31. doi: 10.1182/bloodadvances.2019001287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Brudno JN, Lam N, Vanasse D, Y-W S, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, et al. Safety and feasibility of anti-CD19 CAR T cells with fully humanbinding domains in patients with B-cell lymphoma. Nat Med. 2020;26(2):270–80. doi: 10.1038/s41591-019-0737-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Lanitis E, Poussin M, Klattenhoff AW, Song D, Sandaltzopoulos R, June CH, Powell DJ Jr.. Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol Res. 2013;1(1):43–53. doi: 10.1158/2326-6066.Cir-13-0008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kittel-Boselli E, Soto KEG, Loureiro LR, Hoffmann A, Bergmann R, Arndt C, Koristka S, Mitwasi N, Kegler A, Bartsch T, et al. Targeting acute myeloid leukemia using the RevCAR platform: a programmable, switchable and combinatorial strategy. Cancers. 2021;13(19):4785. doi: 10.3390/cancers13194785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Salzer B, Schueller CM, Zajc CU, Peters T, Schoeber MA, Kovacic B, Buri MC, Lobner E, Dushek O, Huppa JB, et al. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. Nat Commun. 2020;11(1):4166. doi: 10.1038/s41467-020-17970-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Fedorov VD, Themeli M, Sadelain M. PD-1– and CTLA-4–based inhibitory chimeric antigen receptors (iCars) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):ra215172–ra215172. doi: 10.1126/scitranslmed.3006597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Hwang MS, Mog BJ, Douglass J, Pearlman AH, Hsiue E-C, Paul S, DiNapoli SR, Konig MF, Pardoll DM, Gabelli SB, et al. Targeting loss of heterozygosity for cancer-specific immunotherapy. Proc Natl Acad Sci USA. 2021;118(12):e2022410118. doi: 10.1073/pnas.2022410118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Lajoie MJ, Boyken SE, Salter AI, Bruffey J, Rajan A, Langan RA, Olshefsky A, Muhunthan V, Bick MJ, Gewe M, et al. Designed protein logic to target cells with precise combinations of surface antigens. Sci. 2020;369(6511):1637–43. doi: 10.1126/science.aba6527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591):eabe7378. doi: 10.1126/scitranslmed.abe7378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173(6):1426–38.e11. doi: 10.1016/j.cell.2018.03.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Jan M, Scarfò I, Larson RC, Walker A, Schmidts A, Guirguis AA, Gasser JA, Słabicki M, Bouffard AA, Castano AP, et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci Transl Med. 2021;13(575):eabb6295. doi: 10.1126/scitranslmed.abb6295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Zhang R-Y, Wei D, Liu Z-K, Yong Y-L, Wei W, Zhang Z-Y, Lv J-J, Zhang Z, Chen Z-N, Bian H, et al. Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy. Front Cell Dev Biol. 2019;7. doi: 10.3389/fcell.2019.00233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Li H-S, Wong NM, Tague E, Ngo JT, Khalil AS, Wong WW. High-performance multiplex drug-gated CAR circuits. Cancer Cell. 2022;40(11):1294–305.e4. doi: 10.1016/j.ccell.2022.08.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Sahillioglu AC, Toebes M, Apriamashvili G, Gomez R, Schumacher TN. CRASH-IT switch enables reversible and dose-dependent control of TCR and CAR T-cell function. Cancer Immunol Res. 2021;9(9):999–1007. doi: 10.1158/2326-6066.Cir-21-0095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, Sadelain M, Liu L, Jensen MC, Riddell SR, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest. 2016;126(11):4262–72. doi: 10.1172/JCI84813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, Marin V, Marafioti T, Chakraverty R, Linch D, et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood. 2014;124(8):1277–87. doi: 10.1182/blood-2014-01-545020. [DOI] [PubMed] [Google Scholar]
  • 53.Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F, Traversari C, et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Sci. 1997;276(5319):1719–24. doi: 10.1126/science.276.5319.1719. [DOI] [PubMed] [Google Scholar]
  • 54.Di Stasi A, Tey S-K, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–83. doi: 10.1056/NEJMoa1106152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Huang Z, Wu Y, Allen ME, Pan Y, Kyriakakis P, Lu S, Chang Y-J, Wang X, Chien S, Wang Y, et al. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci Adv. 2020;6(8):eaay9209. doi: 10.1126/sciadv.aay9209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Wu Y, Liu Y, Huang Z, Wang X, Jin Z, Li J, Limsakul P, Zhu L, Allen M, Pan Y, et al. Control of the activity of CAR-T cells within tumours via focused ultrasound. Nat Biomed Eng. 2021;5(11):1336–47. doi: 10.1038/s41551-021-00779-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Kosti P, Opzoomer JW, Larios-Martinez KI, Henley-Smith R, Scudamore CL, Okesola M, Taher MYM, Davies DM, Muliaditan T, Larcombe-Young D, et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med. 2021;2(4):100227. doi: 10.1016/j.xcrm.2021.100227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Greenshpan Y, Sharabi O, Ottolenghi A, Cahana A, Kundu K, Yegodayev K, Elkabets M, Gazit R, Porgador A. Synthetic promoters to induce immune-effectors into the tumor microenvironment. Commun Biol. 2021;4(1):143. doi: 10.1038/s42003-021-01664-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014;5. doi: 10.3389/fphar.2014.00254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Spencer DM, Wandless TJ, Schreiber SL, Crabtree GR. Controlling signal transduction with synthetic ligands. Science. 1993;262(5136):1019–24. doi: 10.1126/science.7694365. [DOI] [PubMed] [Google Scholar]
  • 61.Clackson T, Yang W, Rozamus LW, Hatada M, Amara JF, Rollins CT, Stevenson LF, Magari SR, Wood SA, Courage NL, et al. Redesigning an FKBP–ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA. 1998;95(18):10437–42. doi: 10.1073/pnas.95.18.10437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Iuliucci JD, Oliver SD, Morley S, Ward C, Ward J, Dalgarno D, Clackson T, Berger HJ. Intravenous safety and pharmacokinetics of a novel Dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol. 2001;41(8):870–9. doi: 10.1177/00912700122010771. [DOI] [PubMed] [Google Scholar]
  • 63.Foster MC, Savoldo B, Lau W, Rubinos C, Grover N, Armistead P, Coghill J, Hagan RS, Morrison K, Buchanan FB, et al. Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity. Blood. 2021;137(23):3306–9. doi: 10.1182/blood.2021010784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Foster MC, Savoldo B, Lau W, Rubinos C, NS Grover, PM Armistead, JM Coghill, KJ Jamieson, Hagan R, JK Morrison, et al. Abrogation of immune effector cell neurotoxicity syndrome (ICANS) by rimiducid (RIM) in patients treated with CD19-specific chimeric antigen receptor modified T-cells (CAR-T) engineered with an inducible Caspase 9 (iC9 CAR.19)-clinical and pharmacodynamic correlates. Blood. 2022;140:7437–8. [Google Scholar]
  • 65.Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N Engl J Med. 2023;388(14):1284–95. doi: 10.1056/NEJMoa2210859. [DOI] [PubMed] [Google Scholar]

Articles from Human Vaccines & Immunotherapeutics are provided here courtesy of Taylor & Francis

RESOURCES